BP
NRIX icon

BBR Partners’s Nurix Therapeutics NRIX Stock Holding History

BBR Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,988
Closed -$194K – 279
2025
Q3 		$194K Hold
20,988
– – 0.01% 257
2025
Q2 		$239K Hold
20,988
– – 0.01% 209
2025
Q1 		$249K Hold
20,988
– – 0.02% 193
2024
Q4 		$395K Hold
20,988
– – 0.03% 165
2024
Q3 		$472K Hold
20,988
– – 0.04% 141
2024
Q2 		$438K Hold
20,988
– – 0.04% 122
2024
Q1 		$309K Hold
20,988
– – 0.02% 190
2023
Q4 		$217K Hold
20,988
– – 0.02% 167
2023
Q3 		$165K Buy
+20,988
New +$192K 0.02% 183
2023
Q2 		– Sell
-20,988
Closed -$186K – 163
2023
Q1 		$186K Buy
+20,988
New +$219K 0.02% 155

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBR Partners's NRIX Position: Q4 2025 in Review

BBR Partners sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 20,988 shares — an estimated $194K sold.

BBR Partners first reported a position in NRIX in Q1 2023 and held it in 10 quarters. The position peaked at $472K in Q3 2024. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • BBR Partners reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BBR Partners sold 20,988 Nurix Therapeutics shares in Q4 2025, an estimated $194K.
  • BBR Partners first reported a position in Nurix Therapeutics in Q1 2023 and held it in 10 quarters.
  • BBR Partners's Nurix Therapeutics position peaked at $472K in Q3 2024.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on BBR Partners's 13F filing for Q4 2025, filed 11 Feb 2026.